Related Experiment Video
Updated: Jun 30, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Levetiracetam in absence epilepsy
Alberto Verrotti1, Caterina Cerminara, Sergio Domizio
1Department of Paediatrics, University of Chieti, Chieti, Italy.
Developmental Medicine and Child Neurology
|September 24, 2008
Summary
Levetiracetam monotherapy shows promise for treating absence epilepsy in children and adolescents. Many young patients achieved seizure freedom or significant seizure reduction, indicating good tolerability and efficacy.
Area of Science:
- Neurology
- Pediatric Epilepsy
Background:
- Absence epilepsy is a common epilepsy syndrome in children and adolescents.
- Effective and well-tolerated treatment options are crucial for managing this condition.
Purpose of the Study:
- To evaluate the efficacy, tolerability, and safety of levetiracetam as monotherapy for absence epilepsy in pediatric patients.
- To assess seizure control and treatment outcomes over a 12-month period.
Main Methods:
- A prospective study involving 21 children and adolescents with typical absence seizures.
- Patients were treated with levetiracetam monotherapy and evaluated at 6 and 12 months.
- Efficacy was measured by seizure frequency reduction and seizure freedom.
Main Results:
- At 6 months, 11 out of 21 patients were seizure-free, and one experienced a >50% reduction in seizures.
- At 12 months, 10 patients achieved complete seizure freedom, and two showed seizure freedom with EEG anomalies.
- Two patients with no initial improvement demonstrated decreased seizures by the 12-month follow-up.
Conclusions:
- Monotherapy with levetiracetam appears to be effective and well-tolerated in pediatric patients with childhood absence epilepsy and juvenile absence epilepsy.
- Further large-scale, long-term, double-blind studies are warranted to confirm these promising findings.
More Related Videos
Related Concept Videos
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...